# Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

> **NCT01620229** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Fred Hutchinson Cancer Center**

## Conditions studied

- Hematopoietic/Lymphoid Cancer

## Interventions

- **DRUG:** brentuximab vedotin
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01620229
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-06
- **Primary completion:** 2014-04
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-04-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01620229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01620229, "Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01620229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*